FAM114A2

Across TCGA pan-cancer cohorts, FAM114A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM114A2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FAM114A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM114A2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

GBM, PDAC, and HNSC are the cancer types where FAM114A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.228	0.484	.001	17	view →
PDAC	DFS	Median	III,IV	0.512	0.246	.009	17	view →
HNSC	OS	Median	All	0.899	0.814	.026	10	view →
CCRCC	OS	Quartile	III,IV	0.657	0.960	.029	5	view →
LSCC	OS	Tertile	III,IV	0.582	0.986	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM114A2–GBM (DFS)

Open the GBM breakdown →